1. At a Glance
Bajaj Healthcare is attempting a pharma resurrection plot—rebounding from a brutal FY24 to a cautiously optimistic FY25. Between a GenRx acquisition, CDMO deals, and export markets in over 62 countries, it’s cooking up a turnaround story… but does the prescription actually work?
2. Introduction with Hook
Imagine a pharma company going from a -₹84 Cr loss to a ₹40 Cr profit. That’s not a script from a feel-good Bollywood film—it’s Bajaj Healthcare’s FY25 story arc. A minor player with big dreams, this company now claims it’s ready to scale globally through CDMO contracts and strategic acquisitions.
- FY24 Net Loss: ₹-84 Cr
- FY25 Net Profit: ₹40 Cr (yes, from negative to positive)
- Promoter holding: Down from 67.7% to 59.2% in a year (Wait, what?)
Let’s open the prescription file.
3. Business Model (WTF Do They Even Do?)
Bajaj Healthcare Ltd (BHL) is an API + Formulation manufacturer focused on:
- APIs (Active Pharmaceutical Ingredients)
- Nutritional Supplements
- Amino Acids for Pharma, Nutra & Food Industry
Clients? 550+.
Export countries? 62+.
New verticals? CDMO (Contract Development & Manufacturing Organization).
Also acquired GenRx Pharma recently to expand portfolio and access IPs. Revenue is largely domestic but with increasing push toward regulated markets (TGA Australia approval, SEC Phase
